Immunex Corporation

Amgen Inc.

Dauphine S Barone

Kendall M Mohler

Mary K Kennedy

Kara Olson

Kenneth Allan Brasel

Jose Carlos Escobar

Jacqueline A Kirchner

Jacques J Peschon

John D Pluenneke

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

Nucleic acid molecule encoding human GM-CSF antigen binding proteins

Human GM-CSF antigen binding proteins

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&#x3b1; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&#x3b1; inhibitors.

Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.

Growing community of inventors

Seattle, WA, United States of America

Dauphine S Barone